Skip to main content
. 2023 Mar 28;100(13):e1418–e1432. doi: 10.1212/WNL.0000000000206820

Figure 2. Long-term Outcomes of Patients With MOGAD With Tumefactive Lesions.

Figure 2

Kaplan-Meier curves of survival probability estimates of not developing relapse or reaching the EDSS disability milestone of 6 in patients with MOGAD up to 120 months from disease onset, according to the presence of tumefactive lesions. EDSS = Expanded Disability Status Scale; IgG = immunoglobulin G; MOGAD = myelin oligodendrocyte glycoprotein-IgG–associated disease.